The upcoming report from Johnson & Johnson (JNJ) is expected to reveal quarterly earnings of $2.71 per share, indicating a decline of 3.2% compared to the year-ago period. Analysts forecast revenues of $22.38 billion, representing a decrease of 12.3% year over year. Over the last 30 days, there has been a downward revision of 0.3% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe. Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock. While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight. Given this perspective, it's time to examine the average forecasts of specific Johnson & Johnson metrics that are routinely monitored and predicted by Wall Street analysts. The consensus among analysts is that 'Sales- MedTech- Total' will reach $8.21 billion. The estimate suggests a change of +5.4% year over year. Based on the collective assessment of analysts, 'Sales- Innovative Medicine- WW' should arrive at $14.18 billion. The estimate suggests a change of +3.2% year over year. The collective assessment of analysts points to an estimated 'Sales- MedTech- Orthopaedics- Trauma- WW' of $764.77 million. The estimate points to a change of +3.5% from the year-ago quarter. According to the collective judgment of analysts, 'Sales- MedTech- Orthopaedics- Spine, Sports & Other- WW' should come in at $780.35 million. The estimate points to a change of +1.9% from the year-ago quarter. The combined assessment of analysts suggests that 'Sales- MedTech- Orthopaedics- Hips- US' will likely reach $261.14 million. The estimate indicates a change of +4.5% from the prior-year quarter. Analysts predict that the 'Sales- MedTech- Orthopaedics- Hips- International' will reach $146.40 million. The estimate indicates a year-over-year change of -0.4%. Analysts' assessment points toward 'Sales- MedTech- Orthopaedics- Knees- US' reaching $226.07 million. The estimate suggests a change of +2.3% year over year. Analysts forecast 'Sales- MedTech- Orthopaedics- Knees- International' to reach $149.67 million. The estimate suggests a change of +5.4% year over year. The consensus estimate for 'Sales- MedTech- Orthopaedics- Trauma- US' stands at $498.64 million. The estimate indicates a year-over-year change of +3.2%. The average prediction of analysts places 'Sales- MedTech- Orthopaedics- Trauma- International' at $267.83 million. The estimate indicates a change of +5% from the prior-year quarter. It is projected by analysts that the 'Sales- MedTech- Orthopaedics- Spine, Sports & Other- US' will reach $440.94 million. The estimate indicates a year-over-year change of +1.8%. Analysts expect 'Organic Sales Growth (Operational growth)' to come in at 4.9%. Compared to the present estimate, the company reported 7.5% in the same quarter last year. View all Key Company Metrics for Johnson & Johnson here>>> Johnson & Johnson shares have witnessed a change of +2.9% in the past month, in contrast to the Zacks S&P 500 composite's +4.3% move. With a Zacks Rank #3 (Hold), JNJ is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Unlocking Q2 Potential of Johnson & Johnson (JNJ): Exploring Wall Street Estimates for Key Metrics
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...